Europeiska unionen - svenska - EMA (European Medicines Agency)

regeneron ireland designated activity company (dac) - cemiplimab - carcinom, squamous cell - antineoplastiska medel - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

Europeiska unionen - svenska - EMA (European Medicines Agency)

oncopeptides ab - melphalan flufenamide hydrochloride - multipelt myelom - antineoplastiska medel - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

galderma nordic ab - metylaminolevulinathydroklorid - kräm - 160 mg/g - jordnötsolja, raffinerad hjälpämne; cetostearylalkohol hjälpämne; propylparahydroxibensoat hjälpämne; glycerol hjälpämne; metylaminolevulinathydroklorid 200 mg aktiv substans; metylparahydroxibensoat hjälpämne - metylaminolevulinat

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

medartuum ab - metylaminolevulinathydroklorid - kräm - 160 mg/g - cetostearylalkohol hjälpämne; jordnötsolja, raffinerad hjälpämne; glycerol hjälpämne; metylaminolevulinathydroklorid 200 mg aktiv substans; metylparahydroxibensoat hjälpämne; propylparahydroxibensoat hjälpämne - metylaminolevulinat

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

orifarm ab - metylaminolevulinathydroklorid - kräm - 160 mg/g - glycerol hjälpämne; propylparahydroxibensoat hjälpämne; metylaminolevulinathydroklorid 200 mg aktiv substans; metylparahydroxibensoat hjälpämne; cetostearylalkohol hjälpämne; jordnötsolja, raffinerad hjälpämne - metylaminolevulinat

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

paranova läkemedel ab - metylaminolevulinathydroklorid - kräm - 160 mg/g - jordnötsolja, raffinerad hjälpämne; propylparahydroxibensoat hjälpämne; metylparahydroxibensoat hjälpämne; glycerol hjälpämne; cetostearylalkohol hjälpämne; metylaminolevulinathydroklorid 200 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

orifarm ab - metylaminolevulinathydroklorid - kräm - 160 mg/g - propylparahydroxibensoat hjälpämne; jordnötsolja, raffinerad hjälpämne; cetostearylalkohol hjälpämne; glycerol hjälpämne; metylaminolevulinathydroklorid 200 mg aktiv substans; metylparahydroxibensoat hjälpämne

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

paranova läkemedel ab - metylaminolevulinathydroklorid - kräm - 160 mg/g - jordnötsolja, raffinerad hjälpämne; cetostearylalkohol hjälpämne; metylparahydroxibensoat hjälpämne; propylparahydroxibensoat hjälpämne; glycerol hjälpämne; metylaminolevulinathydroklorid 200 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

paranova läkemedel ab - metylaminolevulinathydroklorid - kräm - 160 mg/g - cetostearylalkohol hjälpämne; jordnötsolja, raffinerad hjälpämne; metylparahydroxibensoat hjälpämne; metylaminolevulinathydroklorid 200 mg aktiv substans; glycerol hjälpämne; propylparahydroxibensoat hjälpämne

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

orifarm ab - metylaminolevulinathydroklorid - kräm - 160 mg/g - propylparahydroxibensoat hjälpämne; metylparahydroxibensoat hjälpämne; cetostearylalkohol hjälpämne; jordnötsolja, raffinerad hjälpämne; glycerol hjälpämne; metylaminolevulinathydroklorid 200 mg aktiv substans